ATP

ATP (Advanced Therapy Products) AG was a Swiss biotechnology company focused on the development of innovative cell-based therapies and vaccines. Spun off from the University of Zurich, the company specialized in utilizing dendritic cells and other immunological approaches to target cancer and infectious diseases. Its core technology platform was designed to enhance the body's immune response against specific antigens. The company was notably acquired by the Austrian biotechnology firm Intercell AG in 2004 to strengthen its vaccine pipeline and technology base. Following the acquisition, its operations were integrated into Intercell, which later merged to become part of Valneva SE.